NG004 in Incomplete Spinal Cord Injury Patients (SPROUT-2)
A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Human Monoclonal Antibody NG004 in Acute, Incomplete Cervical Spinal Cord Injury (SCI) Patients
This is a randomized, double-blind, placebo controlled, multicenter trial of NG004 in patients with acute traumatic incomplete cervical SCI. The trial will evaluate the safety and tolerability, PK, and effects on motor function and daily life functioning of NG004 compared with placebo.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Director of Clinical Research
- Telefonnummer: +41433005263
- E-Mail: clinical@novagotx.com
Studienorte
-
-
-
Bayreuth, Deutschland
- Rekrutierung
- Klinik für Querschnittgelähmte, Klinikum Bayreuth
-
Kontakt:
- E-Mail: qs-studien@klinikum-bayreuth.de
-
Bochum, Deutschland
- Noch keine Rekrutierung
- BG Universitätsklinikum Bergmannsheil
-
Halle, Deutschland
- Noch keine Rekrutierung
- Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost
-
Hamburg, Deutschland
- Noch keine Rekrutierung
- BG Klinikum Hamburg
-
Heidelberg, Deutschland
- Rekrutierung
- Klinik für Paraplegiologie, Universitätsklinikum Heidelberg
-
Kontakt:
- E-Mail: NISCI.OUK@med.uni-heidelberg.de
-
Murnau am Staffelsee, Deutschland
- Rekrutierung
- Zentrum für Rückenmarksverletzte, Unfallklinik Murnau
-
Kontakt:
- E-Mail: MNU_SPROUT@bgu-murnau.de
-
Tübingen, Deutschland
- Rekrutierung
- BG Klinik Tübingen
-
Kontakt:
- E-Mail: SPROUT@bgu-tuebingen.de
-
-
-
-
-
Basel, Schweiz
- Rekrutierung
- REHAB Basel
-
Kontakt:
- E-Mail: sprout-Studienteam@rehab.ch
-
Nottwil, Schweiz
- Rekrutierung
- Swiss Paraplegic Centre
-
Kontakt:
- E-Mail: sprout@paraplegie.ch
-
Zurich, Schweiz
- Rekrutierung
- Universitätsklinik Balgrist
-
Kontakt:
- E-Mail: sprout@balgrist.ch
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) with confirmed classification of American Spinal Injury Association (ASIA) impairment scale (AIS) B, C and D at Screening
- 4-28 days post-injury and no earlier than 4 days after spinal surgery
- No required mechanical ventilation or patients that do not completely depend on mechanical ventilation
- Hemodynamically and clinical stable patient according to the acute SCI condition at baseline
Exclusion Criteria:
- Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds
- Multiple levels of clinically relevant spinal cord lesions
- Major brachial or lumbar plexus damage/trauma
- Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function
- Other significant pre-existing or current severe systemic disease
- History of or an episode of multiple sclerosis or Guillain-Barre syndrome
- History of recent meningitis or meningoencephalitis
- History of refractory epilepsy
- Patients with uncontrolled bleeding diathesis and/or who require concomitant therapeutic anticoagulation and not related to SCI
- Presence of any unstable medical or psychiatric condition
- Drug dependence any time within the last 6 months before Screening
- Pregnant or nursing women
- History of a life-threatening allergic or immune-mediated reaction
- Presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections
- Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations
- Patients who are unconscious
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
|
repeated intrathecal injections of Placebo within 30 days |
|
Experimental: NG004
|
repeated intrathecal injections of NG004 within 30 days |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Typ, Häufigkeit, Schweregrad und kausale Beziehung von unerwünschten Ereignissen (AES), schwerwiegenden AES und unerwünschten Arzneimittelreaktionen
Zeitfenster: Von der Behandlung von bis zu 6 Monaten
|
Von der Behandlung von bis zu 6 Monaten
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
NG004 concentration in serum and CSF
Zeitfenster: From treatment start up to 6 months
|
From treatment start up to 6 months
|
|
|
Effect on neurological recovery according to the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol as change in ISNCSCI upper extremities motor score (UEMS) and Integrated Neurological Change Score
Zeitfenster: Baseline to 6 months
|
The ISNCSCI bilateral Upper Extremity Motor Score (UEMS) is determined by examining the muscle function within each of the 5 myotomes encompassing arm and hand function on each side of the body. A score ranging from 0 to 5 can be given to each myotome tested resulting in a maximum score of 50. Higher values indicate better recovery |
Baseline to 6 months
|
|
Effect on daily life functioning as Spinal Cord Independence Measure (SCIM-III)
Zeitfenster: Month 6
|
The SCIM III questionnaire self-care score assesses activities of daily living including feeding, bathing, dressing, and grooming. The self-care score ranges 0-20. The higher scores correspond to better ability to carry out the self-care activities. |
Month 6
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Effect on Graded Redefined Assessment of Strength, Sensation and Prehension (GRASSP): strength and prehension performance
Zeitfenster: Month 6
|
The GRASSP is a validated clinical measure of hand function in tetraplegic patients and can assess changes in impairment over time. The GRASSP (Version 2) consists of 4 subtests. The subtest strength (manual muscle testing of 10 muscles of the upper limb) and the subtest prehension performance (grasping test with 4 activities of daily living) will be performed. |
Month 6
|
|
Effect on the Walking Index for Spinal Cord Injury (WISCI II)
Zeitfenster: Month 6
|
WISCI II is a 21-item hierarchical scale of walking based on physical assistance, need of braces and devices, with an ordinal range from 0 (unable to walk) to 20 (walking without assistance for at least 10 meters). |
Month 6
|
|
Effect on 10-meter walking test (10mWT)
Zeitfenster: Month 6
|
10mWT is a quantitative measurement of lower extremity function. The patient shall walk a set distance (10 meters) at preferred walking speed. The distance covered, the time taken, and the assistance used will be recorded. |
Month 6
|
|
Effect on 6-minute walking test (6MWT)
Zeitfenster: Month 6
|
6MWT is a test used to determine the locomotor performance. Patients are instructed to walk as far as possible during 6 minutes, with rests being taken whenever required. The distance covered in time or until abort, the walking time until abort, and the number of rests are assessed. |
Month 6
|
|
Effect on respiratory function: Forced Vital Capacity (FVC) and Forced Expiratory volume in one second (FEV1)
Zeitfenster: Baseline up to 6 months
|
The various lung parameters will include Forced Vital Capacity (FVC), Forced Expiratory volume in one second (FEV1) and peak expiratory flow (PEF). FVC measures volume in Litter delivered during an expiration made as forcefully and completely as possible starting from full inspiration. FEV1 assess the volume measured in Litter delivered in the first second of a FVC maneuver. PEF measures highest flow delivered during FVC maneuver (L/min). |
Baseline up to 6 months
|
|
Effect on respiratory function: Maximal Inspiratory Pressure [MIP] and Maximum Expiratory Pressure [MEP]
Zeitfenster: Baseline up to 6 months
|
Effect on respiratory function measuring respiratory muscle strength: Maximal Inspiratory Pressure [MIP] and Maximum Expiratory Pressure [MEP]. MIP is assessed as the pressure (in cmH2O) during inhalation against a completely occluded airway and is used to evaluate inspiratory muscle strength. MEP a measure of the strength of expiratory muscles, obtained by having the patient exhale as strongly as possible against a resistance. It is assessed as the pressure (in cmH2O) during exhaling. |
Baseline up to 6 months
|
|
Effect on spinal cord morphology, lesion size, and tissue integrity using magnetic resonance imaging (MRI) scans
Zeitfenster: Baseline to 6 months
|
MRI scans of the spine will be used to characterize the extent of the lesion from the SCI by assessing morphological measures. Analyses of lesion parameters as preserved tissue bridges, lesion volume, lesion length, lesion width and spinal cord atrophy will be performed. Spinal cord atrophy is measured by calculating the cross-sectional area (CSA) of the spinal cord. Quantitative MRI will be used to assess microstructural tissue integrity, as assed by diffusion tensor imaging and quantitative magnetization transfer saturation mapping. |
Baseline to 6 months
|
|
Effect on muscle spasticity (Modified Ashworth Scale [MAS])
Zeitfenster: Month 6
|
MAS is a 6-point muscle tone assessment scale. Scores range from 0 to 4, where lower scores represent normal muscle tone and higher scores represent spasticity or increased resistance to passive movement. |
Month 6
|
|
Effect on neuropathic pain (EMSCI Neuropathic Pain Assessment Form [NePAF])
Zeitfenster: Month 6
|
Neuropathic pain will be assessed by the European Multicenter Study About Spinal Cord Injury (EMSCI) Neuropathic Pain Assessment Form (NePAF), which is based on a structured interview using rating scales, and includes specific assessment of the SCI-associated neuropathic pain in terms of location, quality and severity. The pain intensity is rated with an 11-point numeric rating scale with 0 indicating no pain and 10 indicating the worst imaginable pain. |
Month 6
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NG004-SCI-002
- 2026-526089-26 (EudraCT-Nummer)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .